Genetic and functional analyses do not explain the association of high PRC1 expression with poor survival of breast carcinoma patients

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 857-864

  Brynychova, Veronika ^a,b   Ehrlichova, Marie ^a,b   Hlavac, Viktor ^a,b   Nemcova Furstova, Vlasta ^b   Pecha, Vaclav ^c   Leva, Jelena ^c   Trnkova, Marketa ^d   Mrhalova, Marcela ^e   Kodet, Roman ^e   Vrana, David ^f   Kovar, Jan ^b   Vaclavikova, Radka ^a   Gut, Ivan ^a   Soucek, Pavel ^a,b  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Inst Care Mother and Child   (Czech Republic)

^d Biolab Praha ^*  (Czech Republic)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Breast carcinoma; Cytokinesis; Expression; Genetic; Marker

Indexed keywords

ANTHRACYCLINE; CITRON KINASE; CYCLOPHOSPHAMIDE; FLUOROURACIL; GENOMIC DNA; HORMONE; HORMONE RECEPTOR; KINESIN; PACLITAXEL; PROTEIN; PROTEIN KIF14; PROTEIN REGULATING CYTOKINESIS 1; RHO KINASE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; MESSENGER RNA; PRC1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE SURVIVAL; GENE OVEREXPRESSION; GENE SILENCING; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CASE CONTROL STUDY; CELL DEATH; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; PACLITAXEL; POLYMORPHISM, GENETIC; RNA, MESSENGER;

EID: 84982791082     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.07.047     Document Type: Article

References (40)

1. [1] Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., GLOBOCAN, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. 2008, International Agency for Research on Cancer, Lyon, France.
2. [2] Lee, K.Y., Davies, T., Mishima, M., Cytokinesis microtubule organisers at a glance. J. Cell. Sci. 125 (2012), 3495–3500.
3. [3] Glotzer, M., The 3Ms of central spindle assembly: microtubules motors and MAPs. Nat. Rev. Mol. Cell. Biol. 10 (2009), 9–20.
4. [4] Miki, H., Okada, Y., Hirokawa, N., Analysis of the kinesin superfamily: insights into structure and function. Trends Cell. Biol. 15 (2005), 467–476.
5. [5] Wordeman, L., How kinesin motor proteins drive mitotic spindle function: lessons from molecular assays. Semin. Cell. Dev. Biol. 21 (2010), 260–268.
6. [6] Gruneberg, U., Neef, R., Li, X., Chan, E.H., Chalamalasetty, R.B., Nigg, E.A., et al., KIF14 and CITron kinase act together to promote efficient cytokinesis. J. Cell. Biol. 172 (2006), 363–372.
7. [7] Carleton, M., Mao, M., Biery, M., Warrener, P., Kim, S., Buser, C., et al. RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure. Mol. Cell. Biol. 26 (2006), 3853–3863.
8. [8] Corson, T.W., Huang, A., Tsao, M.S., Gallie, B.L., KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24 (2005), 4741–4753.
9. [9] Corson, T.W., Gallie, B.L., KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int. J. Cancer 119 (2006), 1088–1094.
10. [10] Mollinari, C., Kleman, J.P., Jiang, W., Schoehn, G., Hunter, T., Margolis, R.L., PRC1 is a microtubule binding and bundling protein essential to maintain the mitotic spindle midzone. J. Cell. Biol. 157 (2002), 1175–1186.
11. [11] Hornick, J.E., Karanjeet, K., Collins, E.S., Hinchcliffe, E.H., Kinesins to the core: the role of microtubule-based motor proteins in building the mitotic spindle midzone. Semin. Cell Dev. Biol. 21 (2010), 290–299.
12. [12] Bassi, Z.I., Audusseau, M., Riparbelli, M.G., Callaini, G., P.P. D'Avino, Citron kinase controls a molecular network required for midbody formation in cytokinesis. Proc. Natl. Acad. Sci. USA 110 (2013), 9782–9787.
13. [13] Luo, H.W., Chen, Q.B., Wan, Y.P., Chen, G.X., Zhuo, Y.J., Cai, Z.D., et al. Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer. Biomed. Pharmacother. 78 (2016), 116–120.
14. [14] Chen, J., Rajasekaran, M., Xia, H., Zhang, X., Kong, S.N., Sekar, K., et al. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway. Gut, 2016, 10.1136/gutjnl-2015-310625.
15. [15] Tang, G., Xiao, C., Behrens, J., Schiller, J., Allen, C.W., et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non–small cell lung cancer patients. Clin. Cancer Res. 19 (2013), 1577–1586.
16. [16] Ehrlichova, M., Mohelnikova-Duchonova, B., Hrdy, J., Brynychova, V., Mrhalova, M., Kodet, R., et al. The association of taxane resistance genes with the clinical course of ovarian carcinoma. Genomics 102 (2013), 96–101.
17. [17] Ivshina, A.V., George, J., Senko, O., Mow, B., Putti, T.C., Smeds, J., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 66 (2006), 10292–10301.
18. [18] Mustacchi, G., Sormani, M.P., Bruzzi, P., Gennari, A., Zanconati, F., Bonifacio, D., et al. Identification and validation of a new set of five genes for prediction of risk in early breast cancer. Int. J. Mol. Sci. 14 (2013), 9686–9702.
19. [19] Hubackova, M., Vaclavikova, R., Ehrlichova, M., Mrhalova, M., Kodet, R., Kubackova, K., et al. Association of superoxide dismutases and NAD(P)H oxidoreductases with prognosis of patients with breast carcinomas. Int. J. Cancer. 130 (2012), 338–348.
20. [20] Brynychová, V., Hlaváč, V., Ehrlichová, M., Václavíková, R., Pecha, V., Trnková, M., et al. Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression. Future Oncol. 9 (2013), 427–438.
21. [21] Hlaváč, V., Brynychová, V., Václavíková, R., Ehrlichová, M., Vrána, D., Pecha, V., et al. The expression profile of ABC transporter genes in breast carcinoma. Pharmacogenomics 14 (2013), 515–529.
22. [22] Elston, C.W., Ellis, I.O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991), 403–410.
23. [23] Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000), 205–216.
24. [24] Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55 (2009), 611–622.
25. [25] Barrett, J.C., Fry, B., Maller, J., Daly, M.J., Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005), 263–265.
26. [26] Untergrasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B.C., Remm, M., et al. Primer3–new capabilities and interfaces. Nucleic Acids Res., 10, 2012, e115.
27. [27] Hlaváč, V., Brynychová, V., Václavíková, R., Ehrlichová, M., Vrána, D., Pecha, V., et al. The role of cytochromes P450 and aldo-keto reductases in prognosis of breast carcinoma patients. Medicine (Baltimore), 93, 2014, e255.
28. [28] Ehrlichová, M., Ojima, I., Chen, J., Václavíková, R., Němcová-Fürstová, V., Vobořilová, J., et al. Transport metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells. Naunyn Schmiedebergs Arch. Pharmacol. 385 (2012), 1035–1048.
29. [29] Kunická, T., Václavíková, R., Hlaváč, V., Vrána, D., Pecha, V., Rauš, K., et al. Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer. PLoS One, 9, 2014, e101740.
30. [30] Benjamini, Y., Hochberg, Y., Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B. Met. 57 (1995), 289–300.
31. [31] van't Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A., Mao, M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002), 530–536.
32. [32] Pawitan, Y., Bjöhle, J., Amler, L., Borg, A.L., Egyhazi, S., Hall, P., et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7 (2005), R953–964.
33. [33] Shimo, A., Nishidate, T., Ohta, T., Fukuda, M., Nakamura, Y., Katagiri, T., Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci. 98 (2007), 174–181.
34. [34] Yun, H.J., Cho, Y.H., Moon, Y., Park, Y.W., Yoon, H.K., Kim, Y.J., et al. Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2. Exp. Mol. Med. 40 (2008), 345–353.
35. [35] Wu, L., Hu, X., Tang, H., Han, Z., Chen, Y., Valid application of western blotting. Mol. Biol. Rep. 41 (2014), 3517–3520.
36. [36] Cheung, V.G., Spielman, R.S., Ewens, K.G., Weber, T.M., Morley, M., Burdick, J.T., Mapping determinants of human gene expression by regional and genome-wide association. Nature 437 (2005), 1365–1369.
37. [37] Schiff, P.B., Horwitz, S.B., Taxol stabilizes microtubules in mouse fibroblast cells. PNAS 77 (1980), 1561–1565.
38. [38] Singel, S.M., Cornelius, C., Batten, K., Fasciani, G., Wright, W.E., Lum, L., et al. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. Clin. Cancer Res. 19 (2013), 2061–2070.
39. [39] Singel, S.M., Cornelius, C., Zaganjor, E., Batten, K., Sarode, V.R., Buckley, D.L., et al. KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia 16 (2014), 247–256 (e2).
40. [40] Fu, Y., Huang, J., Wang, K.S., Zhang, X., Han, Z.G., RNA interference targeting CITRON can significantly inhibit the proliferation of hepatocellular carcinoma cells. Mol. Biol. Rep. 38 (2011), 693–702.